Jyothi Subramanian
Overview
Explore the profile of Jyothi Subramanian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Navas T, Kinders R, Lawrence S, Ferry-Galow K, Borgel S, Hollingshead M, et al.
Cancer Res
. 2019 Nov;
80(2):304-318.
PMID: 31732654
The significance of the phenotypic plasticity afforded by epithelial-mesenchymal transition (EMT) for cancer progression and drug resistance remains to be fully elucidated in the clinic. We evaluated epithelial-mesenchymal phenotypic characteristics...
2.
Duggal B, Subramanian J, Duggal M, Singh P, Rajivlochan M, Saunik S, et al.
PLoS One
. 2018 May;
13(5):e0196830.
PMID: 29795604
A prospective, multicenter study was initiated by the Government of Maharashtra, India, to determine predictors of long-term outcomes of percutaneous coronary intervention (PCI) for coronary artery disease, and to compare...
3.
Simon R, Geyer S, Subramanian J, Roychowdhury S
Semin Oncol
. 2016 Mar;
43(1):13-18.
PMID: 26970120
Basket clinical trials are a new category of early clinical trials in which a treatment is evaluated in a population of patients with tumors of various histologic types and primary...
4.
Chimote G, Sreenivasan J, Pawar N, Subramanian J, Sivaramakrishnan H, Sharma S
Drug Des Devel Ther
. 2014 Aug;
8:1107-23.
PMID: 25170251
Background: Anti-angiogenic therapy in certain cancers has been associated with improved control of tumor growth and metastasis. Development of anti-angiogenic agents has, however, been saddled with higher attrition rate due...
5.
Subramanian J, Simon R
Contemp Clin Trials
. 2013 Jul;
36(2):636-41.
PMID: 23811117
The growing recognition that human diseases are molecularly heterogeneous has stimulated interest in the development of prognostic and predictive classifiers for patient selection and stratification. In the process of classifier...
6.
Subramanian J, Simon R
Stat Med
. 2011 Feb;
30(6):642-53.
PMID: 21337359
Resampling techniques are often used to provide an initial assessment of accuracy for prognostic prediction models developed using high-dimensional genomic data with binary outcomes. Risk prediction is most important, however,...
7.
Simon R, Subramanian J, Li M, Menezes S
Brief Bioinform
. 2011 Feb;
12(3):203-14.
PMID: 21324971
Developments in whole genome biotechnology have stimulated statistical focus on prediction methods. We review here methodology for classifying patients into survival risk groups and for using cross-validation to evaluate such...
8.
Subramanian J, Simon R
Nat Rev Clin Oncol
. 2010 Apr;
7(6):327-34.
PMID: 20421890
Most cancer treatments benefit only a minority of patients. This has led to a widespread interest in the identification of gene-expression-based prognostic signatures. Well-developed and validated genomic signatures can lead...
9.
Subramanian J, Simon R
J Natl Cancer Inst
. 2010 Mar;
102(7):464-74.
PMID: 20233996
A substantial number of studies have reported the development of gene expression-based prognostic signatures for lung cancer. The ultimate aim of such studies should be the development of well-validated clinically...
10.
B-Rao C, Subramanian J, Sharma S
Drug Discov Today
. 2009 Feb;
14(7-8):394-400.
PMID: 19185058
Docking, virtual screening and structure-based drug design are routinely used in modern drug discovery programs. Although current docking methods deal with flexible ligands, managing receptor flexibility has proved to be...